human prothrombin complex: clinical use

Prescribing considerations

• Seek input from a clinician experienced in coagulation disorders.
• Reserve use in acquired vitamin K-dependent factor deficiency for situations requiring rapid correction.
• Use a specific individual-factor concentrate for congenital deficiency when available.
• Balance haemostatic benefit against thrombotic and disseminated intravascular coagulation risks.
• Record the product name and batch number for traceability.
• The selected product contains heparin and a clinically relevant sodium load.

Contraindications and cautions

• Hypersensitivity to the active substance or an excipient.
• Known heparin allergy.
• History of heparin-induced thrombocytopenia.

Monitoring

• Clinical control of bleeding and the patient's overall condition.
• Relevant coagulation tests, such as prothrombin time or INR, and individual factor levels where appropriate.
• Signs of hypersensitivity, thrombosis or disseminated intravascular coagulation during and after administration.
• Consider factor inhibitors if the expected clinical or laboratory response is inadequate.
• Exercise particular caution in coronary disease, liver disease, perioperative patients, neonates and others at increased thrombotic risk.

Clinical pharmacology

A four-factor prothrombin complex concentrate that raises circulating factors II, VII, IX and X. Their differing persistence means the haemostatic effect and laboratory response can change over time.

Formulation and product differences

• The selected presentation is a freeze-dried powder supplied with sterile water and a dedicated reconstitution device.
• It contains co-purified protein C, heparin sodium and antithrombin III, plus sodium chloride and sodium citrate.
• The reconstituted product contains no preservative and should generally be used immediately.

Injection

Route: Parenteral

Strengths: 500 units, 1500 units